Payment overview · 2025
General Payments
$199.66
9 reported records · 6 companies
Healthcare provider profile · identity verified
Andrew J. Boyd, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · MC ARTHUR, OH · NPI 1134387723
Verified facts
What the public records show
CMS Open Payments records show Andrew J. Boyd, M.D. received $199.66 in general payments during 2025 across 9 reported records.
Bayer Healthcare Pharmaceuticals Inc. accounted for 44.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 6 associated products.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $89.16 | 44.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $41.26 | 20.7% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $19.94 | 10.0% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $19.36 | 9.7% | 1 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $15.99 | 8.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $13.95 | 7.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $199.66 | 9 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $89.16 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $41.26 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $41.26 | 2 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $19.94 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $19.36 | 1 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $15.99 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
52 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 568 | 128 |
| Amlodipine Besylate | Amlodipine Besylate | 316 | 74 |
| Gabapentin | Gabapentin | 309 | 59 |
| Omeprazole | Omeprazole | 295 | 65 |
| Lisinopril | Lisinopril | 257 | 58 |
| Losartan Potassium | Losartan Potassium | 233 | 56 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 222 | 76 |
| Metoprolol Succinate | Metoprolol Succinate | 180 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 174 | 36 |
| Montelukast Sodium | Montelukast Sodium | 159 | 31 |
| Metformin Hcl Er | Metformin Hcl | 154 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 151 | 28 |
| Carvedilol | Carvedilol | 139 | 33 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 136 | 30 |
| Fluticasone Propionate | Fluticasone Propionate | 131 | 35 |
| Trazodone Hcl | Trazodone Hcl | 115 | 31 |
| Glimepiride | Glimepiride | 112 | 23 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 28 |
| Furosemide | Furosemide | 105 | 32 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 104 | 25 |
| Bupropion Xl | Bupropion Hcl | 101 | 24 |
| Metoprolol Tartrate | Metoprolol Tartrate | 97 | 25 |
| Duloxetine Hcl | Duloxetine Hcl | 95 | 19 |
| Sertraline Hcl | Sertraline Hcl | 95 | 20 |
| Clopidogrel | Clopidogrel Bisulfate | 93 | 27 |
| Ibuprofen | Ibuprofen | 90 | 24 |
| Prednisone | Prednisone | 90 | 45 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 88 | 20 |
| Pregabalin | Pregabalin | 85 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 85 | 23 |
| Pioglitazone Hcl | Pioglitazone Hcl | 82 | 21 |
| Jardiance | Empagliflozin | 79 | 24 |
| Tizanidine Hcl | Tizanidine Hcl | 78 | 18 |
| Meloxicam | Meloxicam | 75 | 14 |
| Alendronate Sodium | Alendronate Sodium | 70 | 12 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 68 | suppressed |
| Simvastatin | Simvastatin | 64 | 16 |
| Eliquis | Apixaban | 63 | 17 |
| Metformin Hcl | Metformin Hcl | 63 | 18 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 62 | 11 |
| Potassium Chloride | Potassium Chloride | 61 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 59 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | 14 |
| Ozempic | Semaglutide | 52 | 12 |
| Escitalopram Oxalate | Escitalopram Oxalate | 50 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 12 |
| Spironolactone | Spironolactone | 49 | 14 |
| Sucralfate | Sucralfate | 49 | suppressed |
| Valsartan | Valsartan | 49 | 20 |
| Ventolin Hfa | Albuterol Sulfate | 49 | 19 |
| Xarelto | Rivaroxaban | 48 | 17 |
| Mirtazapine | Mirtazapine | 47 | 14 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 46 | 11 |
| Chlorthalidone | Chlorthalidone | 45 | 16 |
| Glipizide | Glipizide | 45 | 13 |
| Allopurinol | Allopurinol | 44 | 12 |
| Spiriva Handihaler | Tiotropium Bromide | 44 | 16 |
| Finasteride | Finasteride | 43 | 12 |
| Tramadol Hcl | Tramadol Hcl | 42 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 39 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 38 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 38 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 37 | 13 |
| Famotidine | Famotidine | 36 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 36 | suppressed |
| Ondansetron Odt | Ondansetron | 35 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 35 | 11 |
| Alprazolam | Alprazolam | 34 | suppressed |
| Topiramate | Topiramate | 34 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 33 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 31 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | suppressed |
| Clonazepam | Clonazepam | 30 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 29 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 18 |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 29 | 16 |
| Sumatriptan Succinate | Sumatriptan Succinate | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 26 | suppressed |
| Nitroglycerin | Nitroglycerin | 25 | 21 |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 25 | suppressed |
| Baclofen | Baclofen | 24 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 24 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 23 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 23 | 19 |
| Victoza 3-Pak | Liraglutide | 23 | 11 |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Atenolol | Atenolol | 21 | suppressed |
| Celecoxib | Celecoxib | 21 | suppressed |
| Ezetimibe | Ezetimibe | 20 | suppressed |
| Glipizide Er | Glipizide | 20 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 20 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 20 | suppressed |
| Atrovent Hfa | Ipratropium Bromide | 19 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 19 | 18 |
| Levetiracetam | Levetiracetam | 19 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 19 | suppressed |
| Synthroid | Levothyroxine Sodium | 18 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 17 | suppressed |
| Techlite Pen Needle | Pen Needle, Diabetic | 17 | 11 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 13 |
| Lorazepam | Lorazepam | 16 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 16 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 15 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 15 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 15 | suppressed |
| Naproxen | Naproxen | 15 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 15 | suppressed |
| Tradjenta | Linagliptin | 15 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 15 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 15 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 14 | suppressed |
| Bumetanide | Bumetanide | 14 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 13 |
| Benazepril Hcl | Benazepril Hcl | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 13 | suppressed |
| Brilinta | Ticagrelor | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Methadone Hcl | Methadone Hcl | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 12 | suppressed |
| Victoza 2-Pak | Liraglutide | 12 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Irbesartan | Irbesartan | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 11 | suppressed |
| Ziprasidone Hcl | Ziprasidone Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $199.66 · 9 records | Bayer Healthcare Pharmaceuticals Inc. | Kerendia, Korlym, QULIPTA, SAPIEN 3 Ultra RESILIA, UBRELVY, XIFAXAN | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error